John F. Paolini, Chief Medical Officer of Kiniksa Pharmaceuticals International, plc, filed a Form 4 on November 17, 2026, disclosing five stock option exercises on November 13, 2026, converting a total of 44,126 share options into Class A Ordinary Shares.

Key Highlights

  • Reporting person: John F. Paolini, Chief Medical Officer of Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA)
  • Transaction date: All five exercises occurred on November 13, 2026, with transaction code M (exercise of derivative security)
  • Shares acquired: 29,670 at $10.36, 4,994 at $11.10, 3,723 at $11.97, 3,144 at $12.97, and 2,595 at $15.52 per share
  • All options fully vested: The filing states each option exercised "is fully vested and exercisable"
  • Resulting direct ownership: 114,048 Class A Ordinary Shares held directly following all reported transactions
  • Remaining derivative holdings: Paolini retains options on 196,804 Class A Ordinary Shares across four tranches after the exercises

Paolini's Five-Tranche Option Exercise at Kiniksa Pharmaceuticals

According to the Form 4 filed with the SEC on November 17, 2026, John F. Paolini, Chief Medical Officer of Kiniksa Pharmaceuticals International, plc, executed five separate option exercises on November 13, 2026. All transactions carried transaction code M, indicating the exercise of derivative securities. The filing identifies Paolini's address as care of Kiniksa Pharmaceuticals Int'l, 105 Piccadilly, Second Floor, London, W1J 7NJ, United Kingdom.

The five exercises, all classified as acquisitions (A) in Table I, were as follows: 29,670 Class A Ordinary Shares at $10.36; 4,994 shares at $11.10; 3,723 shares at $11.97; 3,144 shares at $12.97; and 2,595 shares at $15.52. Prior to these transactions, the filing implies a beginning direct holding that stepped up with each exercise, reaching a final direct beneficial ownership of 114,048 Class A Ordinary Shares. All five underlying options were priced at $0 in the derivative table, and the filing notes in its explanation of responses that each option "is fully vested and exercisable."

In Table II, the filing reports the disposition of the corresponding derivative positions. Following the exercises, Paolini's remaining directly held share options include 54,936 options with an exercise price of $11.10 expiring April 6, 2032; 56,207 options at $11.97 expiring August 31, 2032; 38,256 options at $12.97 expiring September 1, 2031; and 47,405 options at $15.52 expiring March 12, 2030. The tranche at $10.36, which had an expiration date of February 29, 2028, shows zero remaining options following the exercise. The Form 4 was signed by Douglas Barry as Attorney-in-Fact on November 17, 2026.

What Was Disclosed

The filing disclosed five fully vested stock option exercises by Kiniksa Pharmaceuticals International's Chief Medical Officer on November 13, 2026, totaling 44,126 Class A Ordinary Shares acquired, with direct beneficial ownership reaching 114,048 shares after all transactions.